Daprodustat (JESDUVROQ): The First HIF-PHD Inhibitor Approved for Anemia in the US

daprodustat

oral, once-daily, pan-PHD inhibitor FDA-approved for anemia in CKD patients designed PHD cofactor mimetic FDA approval, February 1, 2023 GSK, PLC, London, UK

Drug Hunter Team

daprodustat, oral, once-daily, pan-PHD inhibitor FDA-approved for anemia in CKD patients, GSK, PLC, LONDON, UK|2-oxoglutarate, 2-OG, alpha-ketoglutarate, N-oxalylglycine, N-OG, chelate, binding mode, daprodustat|daprodustat, roxadustat, vadadustat, molidustat|compound A, compound B, compound C, compound D

Daprodustat (JESDUVROQ): The First HIF-PHD Inhibitor Approved for Anemia in the US

daprodustat

Other molecules you may be interested in